COVID-19 encephalopathy: Clinical and neurobiological features

Marjolaine Uginet MD1 | Gautier Breville MD1 | Frédéric Assal MD1
Karl-Olof Lövblad MD2 | Maria Isabel Vargas MD2 | Jérôme Pugin MD3
Jacques Serratrice MD4 | Francois R. Herrmann MD, MPH5 | Patrice H. Lalive MD1,6,7
Gilles Allali MD, PhD1,4,8

1Department of Clinical Neurosciences, Division of Neurology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland
2Division of Neuroradiology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
3Division of Intensive Care, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland
4Division of General Internal Medicine, Geneva University Hospital and Faculty of Medicine, University of Geneva, Geneva, Switzerland
5Department of Rehabilitation and Geriatrics, Division of Geriatrics, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
6Diagnostic Department, Division of Laboratory Medicine, Geneva University Hospital, Geneva, Switzerland
7Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
8Department of Neurology, Division of Cognitive and Motor Aging, Albert Einstein College of Medicine, Yeshiva University, Bronx, New York, USA

Correspondence
Gilles Allali, MD, PhD, Department of Neurology, Geneva University Hospitals, 4 Rue Gabrielle-Perret-Gentil, 1211 Geneva, Switzerland.
Email: gilles.allali@hcuge.ch

Funding information
The Private Foundation of the Geneva University Hospitals, Grant/Award Number: N/A

Abstract
Severe acute respiratory coronavirus 2 (SARS-CoV-2) has been associated with neurological complications, including acute encephalopathy. To better understand the neuropathogenesis of this acute encephalopathy, we describe a series of patients with coronavirus disease 2019 (COVID-19) encephalopathy, highlighting its phenomenology and its neurobiological features. On May 10, 2020, 707 patients infected by SARS-CoV-2 were hospitalized at the Geneva University Hospitals; 31 (4.4%) consecutive patients with an acute encephalopathy (64.6 ± 12.1 years; 6.5% female) were included in this series, after exclusion of comorbid neurological conditions, such as stroke or meningitis. The severity of the COVID-19 encephalopathy was divided into severe and mild based on the Richmond Agitation Sedation Scale (RASS): severe cases (n = 14, 45.2%) were defined on a RASS < −3 at worst presentation. The severe form of this so-called COVID-19 encephalopathy presented more often a headache. The severity of the pneumonia was not associated with the severity of the COVID-19 encephalopathy: 28 of 31 (90%) patients did develop an acute respiratory distress syndrome, without any difference between groups (p = .665). Magnetic resonance imaging abnormalities were found in 92.0% (23 of 25 patients) with an intracranial vessel gadolinium enhancement in 85.0% (17 of 20 patients), while an increased cerebrospinal fluid/serum quotient of albumin suggestive of blood-brain barrier disruption was reported in 85.7% (6 of 7 patients). Reverse transcription-polymerase chain reaction for SARS-CoV-2 was negative for all patients in the cerebrospinal fluid. Although different pathophysiological mechanisms may contribute to this acute encephalopathy, our findings suggest the hypothesis of disturbed brain homeostasis and vascular dysfunction consistent with a SARS-CoV-2-induced endotheliitis.

KEYWORDS
COVID-19, encephalopathy, MRI, vasculitis

Marjolaine Uginet and Gautier Breville have contributed equally to this study.
INTRODUCTION

Coronavirus disease-2019 (COVID-19) has been associated with an increased prevalence of acute encephalopathy\(^1\) referred to as COVID-19 encephalopathy. By definition,\(^2\) its clinical and radiological spectrum is heterogeneous.\(^1,3,4\) The severe acute respiratory coronavirus 2 (SARS-CoV-2) may enter into the brain via a hematogenous or a direct trans-nasal route through the olfactory nerve.\(^5\) The physiopathology of this encephalopathy is poorly understood: external factors including intubation and sedative medication, or isolation imposed by the social distancing strategy, as well as specific SARS-CoV-2 related factors may contribute to the encephalopathy.\(^3\)

Early recognition of this acute condition, especially in the intensive care unit (ICU), is key as it has been associated with increased hospital length of stay and higher mortality.\(^6\) We recently reported five patients with a severe form of COVID-19 encephalopathy clinically responsive to steroid suggestive of an inflammatory-mediated mechanism.\(^7\) To better understand its neuropathogenesis, we describe a series of patients with COVID-19 encephalopathy, highlighting its phenomenology and its neurobiological features.

MATERIALS AND METHODS

2.1 Study population

On May 10, 2020, seventy-four days into the COVID-19 outbreak in Geneva (Switzerland), 707 patients infected by SARS-CoV-2 were hospitalized at the Geneva University Hospitals. Among them, 31 (4.4%) were evaluated by a neurologist with a final diagnosis of COVID-19 encephalopathy: 3 in the ICU, 22 in the intermediate care units, and 6 in the standard care unit. SARS-CoV-2 infection was documented by a positive SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) assay from a nasopharyngeal swab at the time of the hospitalization. COVID-19 encephalopathy was defined by a rapidly developing (less than 4 weeks) pathobiological process in the brain leading to delirium, decreased level of consciousness or coma.\(^2\) Here, we focused on our series on patients with delirium or subsyndromal delirium (according to the definition of the consensus statement\(^2\)) at the time of the neurological assessment without etiology, after appropriate delirium screening and exclusion of classical medical etiologies, such as electrolyte disturbances, infection, drug or alcohol toxicity and/or withdrawal,
metabolic disorders, low perfusion state or acute central nervous system conditions, such as stroke or meningitis (Figure 1). We also excluded patients with meningeal enhancement or presence of meningism. The severity of the COVID-19 encephalopathy was divided into severe and mild based on the Richmond Agitation Sedation Scale (RASS): severe cases were defined on a RASS < −3 at worst presentation (meaning deep sedation – no response to voice but possible movement or eye-opening to physical stimulation). Following our inclusion criteria, all patients at the time of the neurological evaluation were not comatose but presented a delirium or a subsyndromal delirium that was quantified by the confusion assessment method (CAM).

| TABLE 1 | Clinical characteristics of patients with COVID-19 encephalopathy at admission |
|---------|--------------------------------------------------------------------------------|
| Total (n = 31) | Severe (n = 14) | Mild (n = 17) | P value* |
| Age (years) | 64.6 ± 12.1 | 65.6 ± 7.8 | 63.8 ± 15.0 | .680 |
| Gender (female), n (%) | 2 (6.5) | 2 (14.3) | 0 (0) | .195 |
| Education, mean (0-3) | 2.30 ± 0.73 | 2.00 ± 0.82 | 2.46 ± 0.66 | .226 |
| Duration before improvement (days) | 12.1 ± 11.3 | 9.3 ± 5.8 | 14.3 ± 14.2 | .212 |
| Duration of COVID-19 symptoms before SACRE onset (days) | 20.9 ± 8.1 | 22.1 ± 6.4 | 19.8 ± 9.3 | .421 |
| ICU (days) (n = 29) | 16.2 ± 7.1 | 18.7 ± 5.1 | 14.1 ± 7.9 | .057 |
| Intubation (days) (n = 28) | 13.2 ± 6.2 | 16.1 ± 4.8 | 10.8 ± 6.4 | .014 |
| Length of stay (days) | 61.4 ± 36.0 | 54.6 ± 19.6 | 66.9 ± 45.3 | .325 |
| Comorbidities, n (%) | | | | |
| Smokingb | 3 (10.0) | 2 (15.4) | 1 (5.9) | .565 |
| Cardiovascular risk factor c (0-4) | 22 (71.0) | 10 (71.4) | 12 (70.6) | 1.000 |
| Body Mass Index (kg/m²) | 28.7 ± 6.1 | 28.9 ± 5.1 | 28.5 ± 6.7 | .873 |
| Chronic cardiac disease d | 8 (25.8) | 4 (28.6) | 4 (23.5) | 1.000 |
| Pulmonary diseases e | 7 (22.6) | 3 (21.4) | 4 (23.5) | 1.000 |
| Dementia f | 3 (10.0) | 0 (0.0) | 3 (17.6) | .238 |
| Alcohol dependence | 2 (6.5) | 2 (14.3) | 0 (0.0) | .195 |
| Symptoms at admission, n (%) | | | | |
| Dyspnea | 22 (71.0) | 11 (78.6) | 11 (64.7) | .456 |
| Chest pain | 1 (3.8) | 1 (10.0) | 0 (0.0) | .385 |
| Cough | 21 (72.4) | 9 (69.2) | 12 (75.0) | 1.000 |
| Fever | 29 (93.5) | 12 (85.7) | 17 (100.0) | .196 |
| Fatigue | 28 (93.5) | 13 (100.0) | 15 (93.8) | 1.000 |
| Myalgia | 9 (40.9) | 5 (55.6) | 4 (30.8) | .384 |
| Diarrhea | 4 (18.2) | 1 (12.5) | 3 (21.4) | 1.000 |
| Disposition | | | | |
| Modified Rankin Scale | 2.42 ± 1.40 | 2.3 ± 1.1 | 2.5 ± 1.6 | .628 |

Abbreviations: COVID-19, coronavirus disease 2019; ICU, intensive care unit.

*a* p value: t test or Fisher exact test.

*b* n = 30 patients.

*c* Cardiovascular risk factors: hypertension; diabetes, dyslipidemia, obstructive sleep apnea.

*d* Chronic cardiac disease: coronary artery disease or congestive heart failure.

*e* Pulmonary diseases: Chronic obstructive pulmonary disease or interstitial lung disease.

*f* Dementia: chronic neurodegenerative disease or vascular dementia.

*g* n = 26 patients.

*h* n = 29 patients.
2.2 | Paraclinical evaluation: Magnetic resonance imaging (MRI), electroencephalogram (EEG), and cerebrospinal fluid (CSF)

Electronic medical records, MRI, EEG, blood, and CSF samples were based upon retrospective chart review and descriptive assessment of the patients during their hospitalization. All clinical and neurological manifestations were reviewed and confirmed by two trained neuroradiologists. A major disagreement between the two neuroradiologists was resolved by the consultation with a third neuroradiologist. MRI (available for 25 patients—12 in the severe COVID-19 encephalopathy group and 13 in the mild group) was acquired on a clinical scanner equipped with a head coil. In addition to a standard scanning neuro head protocol, a post-contrast fat-saturated T1-weighted black blood VISTA was performed in 20 patients (10 patients included in the severe COVID-19 encephalopathy group and 10 in the mild group): MRI was performed on a 1.5 T Philips system equipped with a head coil. The 3D VISTA fat suppressed VISTA (TE, 17 ms; TR, 440 ms; 1.2 mm thickness, 1024 × 1024) sequence was performed in the coronal plane and after iv administration of contrast material (Gadovist, Bayer, Berlin). Axial reconstructions were done in both instances. During contrast administration, a 3D angiogram (TE: 1.98 ms, TR: 5.6 ms, 1.10-mm thick slices) of the carotids was additionally performed as well as post-contrast T1 axial images (TE, 2.46 ms; TR, 262 ms; 5-mm thick slices) over the brain. Suspected inflammation of vessel walls was diagnosed when contrast enhancement of the intracranial vessel wall was concentric and homogeneous: vessel wall enhancement greater than 50% of the circumference. All MRIs were reviewed by two board-certified neuroradiologists. A standard video-EEG in accordance with the international 10-20 system was recorded in 23 patients (12 patients included in the severe COVID-19 encephalopathy group and 11 in the mild group). CSF spinal tap was performed in 8 of 31 patients. The study was approved by the institutional review board of the Geneva University Hospitals (protocol #2020-01206—approved May 25, 2020).

2.3 | Statistical analysis

Baseline characteristics were summarized using means and standard deviations or frequencies and percentages, as appropriate. The normality of data distribution was checked using the Shapiro-Francia test. Between-group comparisons (severe vs. mild COVID-19 encephalopathy) were performed using unpaired t test, Mann-Whitney U test or Fisher exact test, as appropriate. We performed stepwise forward logistic regression models to identify which combination of neurological symptoms was associated with severe COVID-19 encephalopathy. The proportion of the variance explained by the models was estimated by the pseudo-$R^2$. All analyses were conducted using SPSS version 25 (SPSS Inc.).

3 | RESULTS

Clinical characteristics of the 31 patients were compared in Table 1 between the 14 patients with a severe form of COVID-19 encephalopathy and the 17 with a mild form.

The mean age of patients was 64.6 ± 12.1 years with a vast majority of males (93.5%). All females with COVID-19 encephalopathy were severely affected. COVID-19 encephalopathy was present at admission before other symptoms in 6% of patients and started 20.9 ± 8.1 days after COVID-19 symptom onset. The mean duration before clinical improvement of COVID-19 encephalopathy was 12.1 ± 11.3 days. The most common symptoms at admission were fatigue (96.6%), fever (93.5%), and cough (72.4%).

The severity of the pneumonia was not associated with severity of the COVID-19 encephalopathy: 28 of 31 (90%) patients did develop an acute respiratory distress syndrome; the mean O2 request (FiO2) at worst presentation (or right before intubation) was 67.3 ± 15.9%; 28 of 31 (90%) patients were intubated; finally, sepsis was reported in 7 of 31 (22.6%) patients.

The length of stay in the ICU (16.2 ± 7.1 days) and the length of hospital stay (61.4 ± 36.0 days) were similar between the severe and the mild groups. However, the duration of intubation was longer in the severe group in comparison to the mild group. The modified Rankin scale at discharge was 2.42 ± 1.40. 26 of 31 (84%) did not recover and presented a worse mRS at discharge than premorbid. No patients included in the current series died during their hospitalization.

Neurological symptoms and signs are presented in Table 2. Patients with severe versus mild COVID-19 encephalopathy presented more often a headache (60.0% vs. 7.1%; $p = .005$); headache appears before the onset of encephalopathy in 6 of 7 patients (86%). Using a stepwise forward logistic regression model, headache was the only neurological symptom selected by the model with a 12 times risk of developing a severe COVID-19 encephalopathy ($OR = 12.0; 95% CI [1.2–117.4]; p = .033$), explaining 15% of the variability of the severity. Patients with severe versus mild COVID-19 encephalopathy tended to present more often corticospinal tract signs at neurological examination (53.8% vs. 20.0%; $p = .062$). The mean CAM score at neurological assessment was 2.32 ± 1.28. COVID-19 encephalopathy severity (RASS total score at the time of the neurological assessment) was associated with the duration of intubation ($r = -0.443; p = .013$).

MRI abnormalities (Table 2) were reported in 92.0% (23 of 25 patients) with COVID-19 encephalopathy. Noteworthily, intracranial vessel gadolinium enhancement was observed in 85.0% of patients (17 of 20). The vast majority of the vessel enhancement was found on vertebral arteries without sign of stenosis or downstream ische mia (Figure 2 and supplementary materials). Intracranial vessel gadolinium enhancement was confirmed by two board-certified neuroradiologists. Furthermore, inflammatory atheromatous plaques, as a potential cause of such intracranial vessel enhancement, were excluded by angio-MR, angio-CT or echo-doppler. Cerebral microbleeds were reported in 11 of 25 patients (44%): the mean
The number of microbleeds by patients was $16.2 \pm 28.8$; lobar (superficial) distribution of microbleeds was reported in 2 of 11 patients (18.2%), deep in 3 of 11 patients (27.3%), and 6 of 11 patients (54.5%) had a mixed (combination of lobar and deep) distribution. There were no differences in term of MRI abnormalities between severe and mild COVID-19 encephalopathy. Finally, we did not report any T2 or FLAIR hyperintensities in the medial temporal lobe in any patient. No ictal discharge was reported at electroencephalogram (EEG), while EEG slowing was noticed in 73.9% (17 of 23 patients). Serum concentration of C-reactive protein was $57.7 \pm 53.8$ mg/L at the time of the neurological assessment for the all samples; the group with sign of intracranial gadolinium vessel

| Neurological symptoms during hospitalization, n (%) | Total (n = 31) | Severe (n = 14) | Mild (n = 17) | p value$^a$ |
|-----------------------------------------------|---------------|----------------|--------------|-------------|
| Inattention | 26 (83.9) | 14 (100.0) | 12 (70.6) | .048 |
| Obnubilation$^b$ | 17 (63.0) | 9 (81.8) | 8 (50.0) | .124 |
| Disorganized Thinking | 20 (76.9) | 10 (90.9) | 10 (66.7) | .197 |
| Perseveration$^c$ | 22 (91.7) | 9 (90.0) | 13 (92.9) | 1.000 |
| Fluctuation$^d$ | 26 (86.7) | 12 (85.7) | 14 (87.5) | 1.000 |
| Agitation | 16 (51.6) | 8 (57.1) | 8 (47.1) | .722 |
| Hyposmia$^e$ | 4 (36.4) | 1 (33.3) | 3 (37.5) | 1.000 |
| Dizziness$^f$ | 1 (8.3) | 0 (0.0) | 1 (10.0) | 1.000 |
| Hypoacousia$^g$ | 1 (9.1) | 0 (0.0) | 1 (11.1) | 1.000 |
| Headache$^h$ | 7 (29.2) | 6 (60.0) | 1 (7.1) | .009 |

| Neurological signs at neurological evaluation, n (%) | Total (n = 31) | Severe (n = 14) | Mild (n = 17) | p value$^a$ |
|-----------------------------------------------|---------------|----------------|--------------|-------------|
| CAM (total score) | 2.32 ± 1.28 | 2.78 ± 0.70 | 1.94 ± 1.51 | .052 |
| RASS (total score) | −0.77 ± 1.91 | −2.00 ± 1.61 | 0.24 ± 1.52 | <.001 |
| Focal neurological signs$^d$ | 8 (26.7) | 3 (23.1) | 5 (29.4) | 1.000 |
| Corticospinal tract signs$^g$ | 10 (35.7) | 7 (53.8) | 3 (20.0) | .114 |
| Sensory deficit$^i$ | 3 (12.0) | 1 (10.0) | 2 (13.3) | 1.000 |
| Cranial nerve deficit$^d$ | 4 (13.3) | 2 (15.4) | 2 (11.8) | 1.000 |

| MRI (n = 25), n (%) | Total (n = 31) | Severe (n = 14) | Mild (n = 17) | p value$^a$ |
|-----------------------------------------------|---------------|----------------|--------------|-------------|
| MRI abnormalities | 23 (92.0) | 11 (91.7) | 12 (92.3) | 1.000 |
| Any vessels enhancements$^i$ | 17 (85.0) | 9 (90.0) | 8 (80.0) | 1.000 |
| Microbleeds | 11 (44.0) | 6 (50.0) | 5 (38.5) | .695 |

| EEG (n = 23), n (%) | Total (n = 31) | Severe (n = 14) | Mild (n = 17) | p value$^a$ |
|-----------------------------------------------|---------------|----------------|--------------|-------------|
| EEG abnormalities | 17 (73.9) | 9 (75.0) | 8 (72.7) | 1.000 |
| Focal or generalized slowing (delta or theta activities) | 17 (73.9) | 9 (75.0) | 8 (72.7) | 1.000 |
| Focal seizures | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1.000 |

Abbreviations: CAM, confusion assessment method; EEG, electroencephalogram; MRI, magnetic resonance imaging; RASS, Richmond Agitation Sedation Scale.

$^a$p value: t test or Fisher exact test.

$^b$n = 27 patients.

$^c$n = 24 patients.

$^d$n = 30 patients.

$^e$n = 11 patients.

$^f$n = 12 patients.

$^g$n = 28 patients.

$^h$n = 25 patients.

$^i$n = 20 patients.
enhancement presented an increased concentration of C-reactive protein in comparison to those without gadolinium enhancement (63.6 ± 54.6 vs. 6.9 ± 9.5 mg/L; p = .012) (Figure 3). We also measured serum concentration of interleukin-6 (IL-6) in a subsample of patients with post-contrast fat saturated T1-weighted black blood VISTA sequence: 14 in the group with intracranial gadolinium vessel enhancement and 3 in the group without intracranial gadolinium vessel enhancement. Although IL-6 was higher in the group of patients with signs of intracranial gadolinium vessel enhancement than in the group without signs of intracranial gadolinium vessel enhancement, the difference was not significant (766.2 ± 799.7 vs. 161.7 ± 60.7 pg/ml, respectively; p-value = .432). CSF white blood cell count was normal in 8 of 8 patients, whereas CSF/serum quotient of albumin (QAlb—measured in 7 of 8 patients) was increased in 85.7% (mean QAlb = 11.6 ± 5.5). RT-PCR for SARS-CoV-2 was negative for all patients in the CSF (measured in 7 of 8).

Among the 31 patients, 2 patients were treated by high-dose steroid (methylprednisolone 0.5 g/d iv for 5 days) due to a prolonged delirium without any improvement. Following steroid initiation, both patients presented a clinical improvement with resolution of delirium.

4 | DISCUSSION

We report on a series of patients with COVID-19 encephalopathy, including clinical and neurobiological features. The prevalence of COVID-19 encephalopathy in our series is certainly underestimated, as patients hospitalized for SARS-CoV-2 infection were not systematically screened by a neurologist, but evaluated only when the referral physicians (internists or intensivists) asked for a neurological consult; patients with subtle signs may have been not identified by the referral physicians.

In this consecutive series of COVID-19 encephalopathy, (i) clinical findings (high prevalence of headache in severe patients), (ii) neuroradiological signs (high proportion of gadolinium enhancement in large intracranial arteries) and (iii) biological features (increase CSF QAlb suggestive of blood-brain barrier disruption) may suggest among other mechanisms a pathophysiological mechanism related to an inflammation of the vessel wall for COVID-19 encephalopathy development – the endothelial hypothesis. Although the comparison is limited, as our current series does not include patients with stroke, such endothelial dysfunction has been demonstrated on a brain biopsy of a patient with temporal hematoma and subarachnoid hemorrhage. Non-convulsive status or infraclinical seizures were ruled out by routine EEG that were consistent with the recent description of EEG findings in critically ill patients with COVID-19. A hypoxemia-induced encephalopathy may an alternative hypothesis, as the majority of our cohort has been intubated (28 of 31) due to the severity of pneumonia and an acute respiratory distress syndrome. However, the severity of the COVID-19 encephalopathy was not associated with the severity of pneumonia. An immunopathogenic mechanism related to COVID-19 has been proposed in other neurological complications of the SARS-CoV-2 infection, for example in cases of Guillain-Barre syndrome or of limbic encephalitis. However, absence of white matter lesion and absence of meningeal or parenchymal gadolinium enhancement on MRI, and absence of pleocytosis in the CSF are not in favor of such hypothesis. The elevation of C-reactive protein in patients with
COVID-19 encephalopathy with intracranial gadolinium vessel enhancement may also suggest an inflammatory mediated mechanism for this COVID-19 encephalopathy. In addition, whether serum concentration of IL-6, one of the pro-inflammatory cytokines involved in the so-called cytokine storm, was higher in the group of patients with contrast enhancement of intracranial vessels in comparison to those without enhancement, this difference was not significant. Finally, the use of sedative-hypnotic and anticholinergic agents in critical ill COVID-19 patients, unstable comorbidities, or social isolation are many factors that possibly contribute to delirium in COVID-19. Furthermore, the CSF biological findings—increased CSF QAlb, CSF white blood cell count within normal range, and the absence of direct proof of SARS-CoV-2 in the CSF—are in favor of an indirect (or inflammatory) effect of SARS-CoV-2 for explaining this encephalopathy. This hypothesis supports the rationale of a steroid-responsive encephalopathy, as recently reported by our group and others. It is of note that the role of steroids in the clinical improvement of our patients and others needs to be confirmed in future prospective studies, as the majority of our patients spontaneously recovered from encephalopathy without steroids.

Although the neuropathogenesis of COVID-19 encephalopathy is still unknown, this observation suggests the hypothesis of disturbed brain homeostasis and vascular dysfunction consistent with the recent description of a SARS-CoV-2-induced endotheliitis in autopsy. However, we should acknowledge that in the current series, we did not have any histological evidence of endotheliitis or vasculitis in other organs, as reported by others. Finally, the patients included in this cohort did not have any clinical evidence of vasculitis in other organs, explaining why we did not perform a standardized screening for autoimmune vasculitis.

Others and our group suggested that the phenomenon of “happy or silent hypoxemia”—hypoxemia without dyspnea—reported in many patients with severe COVID-19 pneumonia could be the consequence of inappropriate cortical processing of interoceptive information from the respiratory system. Dyspnea perception involves the activation of various cortical regions, especially the insula, and the presence of COVID-19 encephalopathy may interfere with such a physiological complex mechanism of dyspnea perception. In the current series, the prevalence of dyspnea was similar between severe and mild encephalopathy. Therefore, we are not able to support the hypothesis suggesting that severe COVID-19 encephalopathy may be associated with the phenomenon of “happy or silent hypoxemia.” Future studies should investigate this hypothesis by quantifying the severity of the dyspnea with appropriate questionnaires.

This retrospective study has some limitations. Although we followed strict inclusion criteria for COVID-19 encephalopathy (delirium or subsyndromal delirium without cause), only subgroups of patients underwent a different evaluation: MRI in 81%, EEG in 74%, and CSF analysis in 26% of patients. Although we could not definitively rule out encephalitis in the 23 patients without CSF analyses, the clinical decision to exclude the CSF analyses was done after a diagnostic conference involving neurologists and internal medicine physicians based on the follow-up and common medical knowledge at the time of the pandemic, namely that SARS-CoV-2 rarely produces encephalitis. An MRI and an EEG were not available for 3 patients; however, the clinical presentation (delirium at a distance of pneumonia) and follow-up of these patients were highly suggestive of COVID-19 encephalopathy. Finally, we should acknowledge that none of the patients died during their hospitalization; this may suggest that the patients with the most severe COVID-19 pneumonia (those who eventually died) were not referred for a neurological consult and consecutively not included in this series; that would restrict the generalization of the study findings to patients with COVID-19 encephalopathy, who survive during their hospitalization.

5 | CONCLUSIONS

At this time of the pandemic, recognition of COVID-19 encephalopathy and appropriate treatment are needed, as the long-term neuropsychiatric consequences of this encephalopathy are not yet established, and that the evolution of the pandemic depends on various unknown scenarios.

ACKNOWLEDGMENTS

This study has been performed in the Geneva University Hospitals. This study was funded by a donor from the Private Foundation of the Geneva University Hospitals.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS

Conception and design of the study: Frédéric Assal, Patrice H. Lalive, and Gilles Allali. Acquisition and analysis of data: Marjolaine Uginet, Gautier Breville, Frédéric Assal, Karl-Olof Lövblad, Maria Isabel Vargas, Jérôme Pugin, Jacques Serratrice, Patrice H. Lalive, and Gilles Allali. Drafting the manuscript: Gilles Allali and all authors critically revised the drafted manuscript and approved the submitted manuscript.

ETHICS APPROVAL STATEMENT

The study was approved by the institutional review board of the Geneva University Hospitals (protocol #2020-01206 – approved May 25, 2020).

DATA AVAILABILITY STATEMENT

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

ORCID

Gilles Allali  http://orcid.org/0000-0002-4455-6719

REFERENCES

1. Koralnik IJ, Tyler KL. COVID-19: a global threat to the nervous system. Ann Neurol. 2020;88:1-11.
2. Slooter AJC, Otte WM, Devlin JW, et al. Updated nomenclature of delirium and acute encephalopathy: statement of ten societies. Intensive Care Med. 2020;46:1020-1022.
3. Kotfis K, Williams Roberson S, Wilson JE, Dabrowski W, Pun BT, Ely EW. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. Crit Care. 2020;24:176.
4. Kremer S, Lersy F, Anheim M, et al. Neurologic and neuroimaging findings in patients with COVID-19: A retrospective multicenter study. Neurology. 2020;95:e1888-e1882.
5. LiYC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020;92:552-555.
6. Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004;291:1753-1762.
7. Pugin D, Vargas MI, Thieffry C, et al. COVID-19-related encephalopathy responsive to high doses glucocorticoids. Neurology. 2020;95:543-546.
8. Lindenholz A, van der Kolk AG, Zwanenburg JJM, Hendrikse J. The use and pitfalls of intracranial vessel wall imaging: how we do it. Radiology. 2018;286:12-28.
9. Liotta EM, Batra A, Clark JR, et al. Frequent neurologic manifestations and encephalopathy-associated morbidity in COVID-19 patients. Ann Clin Transl Neurol. 2020;7:2221-2230.
10. Hernández-Fernández F, Sandoval Valencia H, Barbella-Aponte RA, et al. Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. Brain. 2020;143:3089-3103.
11. Vespignani H, Colas D, Lavin BS, et al. Report of EEG finding on critically ill patients with COVID-19. Ann Neurol. 2020;88:626-630.
12. Filosto M, Cotti Piccinelli S, Gazzina S, et al. Guillain-Barre syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry. 2020;jnnp-2020-324837.
13. Zambreanu L, Lightbody S, Bhandari M, et al. A case of limbic encephalitis associated with asymptomatic COVID-19 infection. J Neurol Neurosurg Psychiatry. 2020;91:1229-1230.
14. Pilotto A, Odolini S, Stefano Masciocchi S, et al. Steroid-responsive encephalitis in COVID-19 disease. Ann Neurol. 2020;88(2):423-427.
15. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417-1418.
16. Allali G, Marti C, Grosgerin O, Morelot-Panzini C, Similowski T, Adler D. Dyspnea: the vanished warning symptom of COVID-19 pneumonia. J Med Virol. 2020;92:2272-2273.
17. Couzin-Frankel J. The mystery of the pandemic’s ‘happy hypoxia’. Science. 2020;368:455-456.
18. Burki NK, Lee LY. Mechanisms of dyspnea. Chest. 2010;138:1196-1201.

SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Uginet M, Breville G, Assal F, et al. COVID-19 encephalopathy: Clinical and neurobiological features. J Med Virol. 2021;93:4374-4381. https://doi.org/10.1002/jmv.26973